#ADC #Mabwell #7MW3711

Mabwell to Present Latest Clinical Data on 7MW3711

Mabwell, a leading biopharmaceutical company based in Shanghai, has announced that it will present the results of its clinical research on the groundbreaking B7-H3-targeting antibody-drug conjugate (ADC), known as 7MW3711, at the 2025 European Society for Medical Oncology (ESMO) Congress. This event is pivotal for oncological developments, and Mabwell's participation highlights their commitment to advancing cancer therapies.

As of September 15, 2025, the clinical study that forms the basis for this presentation has involved 74 patients suffering from various advanced solid tumors. Among these patients, those treated with a dosage of 4.0 mg/kg or higher and who went through tumor assessments demonstrated notable outcomes, with 19 cases resulting in either a partial response (PR) or a complete response (CR).

Highlights of the Clinical Study

Within the cohort of patients diagnosed with esophageal cancer (EC), the study highlights an objective response rate (ORR) of 42.9%, achieving a remarkable disease control rate (DCR) of 100%. For patients battling lung cancer, distinct patient groups yielded impressive results: those with small cell lung cancer (SCLC) and squamous non-small cell lung cancer (Sq-NSCLC) had ORRs of 50% and 38.5%, respectively, with DCRs reaching as high as 90% and 92.3%.

What's particularly encouraging is that there were no dose-limiting toxicities (DLTs) observed during the dose escalation phase of the trials, and the maximum tolerated dose (MTD) remains unexplored at this time. However, the study did report some Grade ≥3 treatment-emergent adverse events (TEAEs), such as reduced white blood cell and neutrophil counts, anemia, and decreased platelet levels, which are essential for monitoring the drug's safety profile.

About 7MW3711

The ADC, 7MW3711, specifically targets the B7-H3 protein, which presents a unique challenge and opportunity in cancer treatment. Its design showcases a stable structure and a homogeneous composition combined with high purity levels, paving the way for broader industrial applications. Compared to worldwide counterparts, 7MW3711 exhibits significant tumor-killing efficacy across multiple animal models.

Utilizing an innovative camptothecin payload, 7MW3711 outperforms other payloads, demonstrating superior antitumor activity in preclinical studies. The use of site-specific conjugation technology further enhances the drug's consistency, ensuring optimal stability across varied patient batches. Its unique design allows for payload release through protease hydrolysis within tumor tissues, ultimately boosting its systemic stability in human subjects.

In safety evaluations conducted on cynomolgus monkeys, 7MW3711 has consistently displayed commendable safety and pharmacokinetic properties, which are crucial for its future development and utilization.

Mabwell's Commitment to Innovation

Mabwell's overarching goal is to bridge the gap in treatment options for patients with significant unmet medical needs, particularly in oncology. As an innovation-driven biopharmaceutical company, they are dedicated to enhancing accessibility to effective treatments while exploring new avenues in medical science. Their mission,